The global pharmaceutical analytical testing outsourcing market size was valued at USD 7.6 billion in 2022 and is anticipated to grow a compound annual growth rate (CAGR) of 8.4% from 2023 to 2030. The key factors driving the market are innovation in the pharmaceutical industry, increasing focus on regulation, safety, quality, rising number of end-users, and the pricing benefits of outsourcing. Small and medium-sized pharmaceutical companies do not have the necessary infrastructure to support various types of analytical testing. As a result, outsourcing these processes is the best alternative as it saves time and money. The COVID-19 pandemic has increased the demand for pharmaceuticals. During this crisis, global pharmaceutical analytical testing outsourcing providers played a predominant role in meeting the testing needs of pharmaceutical companies, biotech companies, contract research organizations, and other end users.
These organizations have been actively working towards the development of pharmaceutical samples, APIs, small and large molecules, and other pharmaceutical products. The increase in the number of cases of COVID-19 is expected to improve the demand for these services, which is expected to have a positive impact on the market for pharmaceutical analytical testing outsourcing.
Other factors, such as the increasing need for product safety and quality, along with changing regulations for in vivo and in vitro tests, are also expected to propel the growth of the market for pharmaceutical analytical testing outsourcing. For instance, the government of China issued a notification to upgrade the quality of generic drugs, remove the backlog of drug applications, improve the quality and transparency of the review and approval process, and encourage new drug R&D in line with global development.
The economic benefits associated with outsourcing these services and approvals in the pharmaceutical industry are projected to support market growth. Quicker and more reliable results, data safety, and improved efficiency are some of the key factors favoring market growth. Innovation or new product development is directly proportional to the demand for testing services. Due to competitive pressures, pricing concerns, and lead-time to market, companies are opting to outsource testing services. According to the Pharma Intelligence Report 2021, the total drugs in the pipeline increased to 18,852 molecules in 2021 from 17,737 molecules in 2020.
An increasing focus on customized care and technological advancements are shortening the product lifecycle, which has resulted in the rapid development of new products. The development of combination products, biosimilar, and other innovative medicines has led to an increase in demand for specific types of tests. Outsourcing services are becoming the most preferable option for many pharma companies to increase operational efficiency, therapeutic expertise, and on-demand services along with the expansion of geographical presence.
As per the WHO, the COVID-19 pandemic has significantly increased the demand for biological medicines like vaccines. As of April 15th, 2022, over 349 vaccines were under development as per the WHO. This is expected to improve the demand for analytical testing services for COVID-19 vaccines under clinical trials. Apart from this, several outsourcing companies have helped pharma companies in testing drugs for COVID-19. For instance, Eurofins Scientific supported the testing of an investigational COVID-19 vaccine candidate by Johnson & Johnson. Similarly, SGS supported AstraZeneca and the University of Oxford to test the ingredients of their vaccine candidate. These actions by the outsourcing service providers are expected to have a positive impact on the market for pharmaceutical analytical testing outsourcing.
The other service segment accounted for a revenue share of over 39.3% in 2022. The segment includes environmental monitoring, raw material testing, batch release, microbial testing, and physical characterization of the materials. Changing regulations for in vivo and in vitro tests and innovative approaches to reduce the complexity of the tests are contributing to the segment’s growth.
The bioanalytical testing services segment is expected to witness the fastest growth over the forecast period. The entry of new participants into the market and an increasing number of clinical trial registrations have contributed to the segment’s growth. A lot of small-scale industries are not equipped with top-end analytical tools and opt for outsourcing these studies to industry experts having years of experience in performing, documenting, and adapting to the challenges presented during analysis. This is also anticipated to drive segment growth.
The pharmaceutical companies segment dominated the market for pharmaceutical analytical testing outsourcing and accounted for a revenue share of over 47.3% in 2022. There are a significant number of small-sized pharmaceutical companies globally that lack in-house analytical testing capabilities. This has encouraged small-sized pharmaceutical companies to collaborate with CROs to assist them with analytical testing services. Outsourcing analytical testing services also saves time for the pharmaceutical company, thus helping them focus on their core competence. This further supports the growth of the segment market.
The biopharmaceutical companies’ segment is expected to witness the fastest CAGR of 8.7% over the forecast period. Biopharmaceutical companies are required to do analytical testing to improve productivity, characterize biologics and biosimilars, and provide real-time product quality control. Biopharmaceutical analytical testing requires specialized staff to run the assays and prepare regulatory filings. This reason has significantly contributed to the demand for outsourcing biopharmaceutical analytical services to an expert team and thus is expected to have a positive impact on the segment market.
North America dominated the pharmaceutical analytical testing outsourcing industry and accounted for the largest revenue share of over 53.4% in 2022 and will retain its dominant position throughout the forecast years. This is because the region is one of the top manufacturing hubs for complex, highly reliable, and high-end pharmaceuticals.
The rise in the manufacturing of pharmaceuticals to meet the increasing demand for efficient healthcare in the region is also projected to be one of the major factors propelling the market growth.
In Asia Pacific, the market for pharmaceutical analytical testing outsourcing is expected to grow at a rapid pace from 2023 to 2030 as a lot of developed countries are investing in countries in this region. Outsourcing services in APAC are usually supported by delivery centers in the Philippines, China, and India. China is gaining popularity as a delivery location for nearshore and onshore clients based out of Japan.
Key players in the global pharmaceutical analytical testing outsourcing market are undertaking various strategic initiatives, such as mergers and acquisitions, collaboration, and service portfolios as well as geographic expansions, to gain a higher market share. For instance, in December 2021, SGS SA acquired Quay Pharma, a pharma R&D organization to expand its capability in biopharmaceutical analytical testing. Similarly, in May 2019, Intertek Group Plc announced the expansion of its pharmaceutical services laboratory in Milbourn. Some of the prominent players in the global pharmaceutical analytical testing outsourcing market include:
SGS S.A.
Labcorp
Eurofins Scientific
Pace Analytical Services, Inc.
Intertek Group Plc
PPD Inc. (Thermo Fisher Scientific)
WuXi AppTec
Boston Analytical
Charles River Laboratories
West Pharmaceutical Services Inc.
Report Attribute |
Details |
Market size value in 2023 |
USD 8.2 billion |
Revenue forecast in 2030 |
USD 14.5 billion |
Growth rate |
CAGR of 8.4% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Report updated |
April 2023 |
Quantitative units |
Revenue in USD billion and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Service, end-use, region |
Regional scope |
North America; Europe; Asia Pacific, Latin America, MEA |
Country scope |
U.S.; Canada; UK; Germany; France; Italy; Spain; Russia; Netherlands; Switzerland; Turkey; Sweden; Japan; China; India; Australia; South Korea; Indonesia; Malaysia; Singapore; Thailand; Taiwan; Brazil; Mexico; Argentina; Colombia; Chile; South Africa; Saudi Arabia; UAE; Egypt; Israel |
Key companies profiled |
SGS SA; Labcorp; Eurofins Scientific; Pace Analytical Services, Inc.; Intertek Group Plc; PPD Inc (Thermo Fisher Scientific, Inc); WuXi AppTec; Boston Analytical; Charles River Laboratories; West Pharmaceutical Services Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 - 2030. For this study, Grand View Research has segmented the global pharmaceutical analytical testing outsourcing market report based on services, end-use, and region:
Services Outlook (Revenue, USD Million; 2018 - 2030)
Bioanalytical Testing
Clinical
Non-clinical
Method Development & Validation
Extractable & Leachable
Impurity Method
Technical Consulting
Others
Stability Testing
Drug Substance
Stability Indicating Method Validation
Accelerated Stability Testing
Photostability Testing
Others
Others
End-use Outlook (Revenue, USD Million; 2018 - 2030)
Pharmaceutical Companies
Biopharmaceutical Companies
Contract Research Organizations
Regional Outlook (Revenue, USD Million; 2018 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Russia
Turkey
Netherlands
Switzerland
Sweden
Asia Pacific
Japan
China
India
Australia
South Korea
Indonesia
Malaysia
Singapore
Thailand
Taiwan
Latin America
Brazil
Mexico
Argentina
Colombia
Chile
Middle East & Africa
South Africa
Saudi Arabia
UAE
Egypt
Israel
b. The global pharmaceutical analytical testing outsourcing market size was estimated at USD 7.6 billion in 2022 and is expected to reach USD 8.2 billion in 2023.
b. The global pharmaceutical analytical testing outsourcing market is expected to grow at a compound annual growth rate of 8.4% from 2023 to 2030 to reach USD 14.6 billion by 2030.
b. North America dominated the pharmaceutical analytical testing outsourcing market with a share of 53.9% in 2022. This is attributable to the rapid increase in the manufacturing of pharmaceuticals to meet the rising demand for efficient healthcare.
b. Some key players operating in the pharmaceutical analytical testing outsourcing market include Labcorp; Intertek Group PLC; SGS SA; Eurofins Scientific; Boston Analytical; Pace Analytical Services, LLC; West Pharmaceutical Services, Inc.; WuXi AppTec; Intertek Group Plc; PPD Inc; and Charles River Laboratories.
b. Key factors that are driving the pharmaceutical analytical testing outsourcing market growth include increasing demand for analytical drugs, biosimilars, and biopharmaceuticals as well as increasing investments in R&D for pharmaceuticals, rising demand for product safety and quality, and changing regulations for in-vivo and in-vitro tests.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.